Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Authors
Keywords
-
Journal
LANCET
Volume 399, Issue 10342, Pages 2200-2211
Publisher
Elsevier BV
Online
2022-06-10
DOI
10.1016/s0140-6736(22)00688-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results
- (2022) Geert R. D‘Haens et al. GASTROENTEROLOGY
- Su451 TREATMENT PATTERNS IN BIOLOGIC-EXPERIENCED CROHN'S DISEASE PATIENTS USING THREE LARGE COMMERCIAL CLAIMS DATABASES IN THE UNITED STATES
- (2021) Amanda M. Teeple et al. GASTROENTEROLOGY
- Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
- (2021) Yanna Ko et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
- (2021) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA
- (2021) Zhijie Ding et al. Drugs - Real World Outcomes
- Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
- (2020) Camilo Obando et al. ADVANCES IN THERAPY
- Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
- (2020) Laura E Targownik et al. Journal of Crohns & Colitis
- Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
- (2018) S. Singh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
- (2016) J. Cosnes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
- (2014) Uri Kopylov et al. Journal of Crohns & Colitis
- Advanced multiplicity adjustment methods in clinical trials
- (2013) Mohamed Alosh et al. STATISTICS IN MEDICINE
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
- (2009) Jean-Frédéric Colombel et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started